Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSS NASDAQ:GRCE NASDAQ:MIRA NASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$0.19+12.5%$0.23$0.14▼$3.87$45.74M2.0413.87 million shs16.45 million shsGRCEGrace Therapeutics$2.53+6.8%$2.30$1.79▼$5.18$41.17M0.37486,173 shs273,288 shsMIRAMIRA Pharmaceuticals$0.95+1.1%$0.99$0.90▼$2.45$40.13M1.48141,257 shs68,431 shsMTEXMannatech$5.04-2.3%$5.09$3.80▼$12.45$9.73M0.7224,467 shs6,947 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+8.25%-1.03%-49.93%-85.86%GRCEGrace Therapeutics0.00%-0.21%+3.04%-41.77%-24.28%MIRAMIRA Pharmaceuticals0.00%-6.46%-5.52%-12.52%-19.59%MTEXMannatech0.00%+1.78%-9.47%-6.18%-44.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$0.19+12.5%$0.23$0.14▼$3.87$45.74M2.0413.87 million shs16.45 million shsGRCEGrace Therapeutics$2.53+6.8%$2.30$1.79▼$5.18$41.17M0.37486,173 shs273,288 shsMIRAMIRA Pharmaceuticals$0.95+1.1%$0.99$0.90▼$2.45$40.13M1.48141,257 shs68,431 shsMTEXMannatech$5.04-2.3%$5.09$3.80▼$12.45$9.73M0.7224,467 shs6,947 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+8.25%-1.03%-49.93%-85.86%GRCEGrace Therapeutics0.00%-0.21%+3.04%-41.77%-24.28%MIRAMIRA Pharmaceuticals0.00%-6.46%-5.52%-12.52%-19.59%MTEXMannatech0.00%+1.78%-9.47%-6.18%-44.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 2.20Hold$4.502,243.75% UpsideGRCEGrace Therapeutics 2.00Hold$6.00136.31% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/AMTEXMannatech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, MIRA, GOSS, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.006/24/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/19/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$55.54M0.81N/AN/A($0.53) per share-0.36GRCEGrace TherapeuticsN/AN/AN/AN/A$4.13 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/AMTEXMannatech$108.04M0.09N/AN/A($2.75) per share-1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$170.37M-$0.79N/AN/AN/A-324.82%N/A-96.10%8/4/2026 (Estimated)GRCEGrace Therapeutics-$7.79M-$0.48N/AN/AN/AN/A-14.45%-13.58%8/11/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.30N/AN/AN/AN/A-140.82%-135.01%9/2/2026 (Estimated)MTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/ALatest MTEX, MIRA, GOSS, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/18/2026Q4 2026GRCEGrace Therapeutics-$0.24-$0.07+$0.17-$0.06$0.90 millionN/A5/15/2026Q1 2026GOSSGossamer Bio-$0.17-$0.20-$0.03-$0.20$4.67 million$16.96 million5/14/2026Q1 2026MIRAMIRA PharmaceuticalsN/A-$0.03N/A-$0.03N/AN/A5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer BioN/A2.202.20GRCEGrace TherapeuticsN/A8.108.10MIRAMIRA PharmaceuticalsN/A82.1582.15MTEXMannatechN/A1.090.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%GRCEGrace Therapeutics6.08%MIRAMIRA Pharmaceuticals35.16%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio3.74%GRCEGrace Therapeutics11.10%MIRAMIRA Pharmaceuticals6.65%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180234.70 million225.92 millionOptionableGRCEGrace TherapeuticsN/A16.27 million14.47 millionN/AMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableMTEXMannatech2501.93 million1.13 millionNot OptionableMTEX, MIRA, GOSS, and GRCE HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Stock Price Passes Below 200-Day Moving Average - Should You Sell?June 30, 2026 | americanbankingnews.comMannatech Announces Appointment of Yasir Haider as Chief Financial OfficerJune 8, 2026 | globenewswire.comMannatech, Incorporated Announces Successful Approval of All Proposals at Annual Shareholder MeetingJune 3, 2026 | quiverquant.comQMannatech Announces Results of Annual Shareholders' MeetingJune 3, 2026 | globenewswire.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 2,803 Shares of StockMay 22, 2026 | insidertrades.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 5,000 Shares of StockMay 21, 2026 | insidertrades.comMannatech Stock Price HistoryMay 20, 2026 | investing.comMannatech Reports Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | markets.businessinsider.comMannatech, Incorporated Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | quiverquant.comQMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | globenewswire.comMannatech, IncorporatedApril 8, 2026 | edition.cnn.comMannatech Delays 10-K Filing Amid Going-Concern ReviewApril 2, 2026 | tipranks.comMannatech Announces Notification of Late FilingApril 1, 2026 | markets.businessinsider.comMannatech Inc. Reports Improved Quarterly Earnings Amid Sales DeclineNovember 13, 2025 | msn.comMannatech Reports Financial Results for Third Quarter 2025November 12, 2025 | globenewswire.comMicro-Cap Mannatech Stock Draws Frenzied Retail Buzz As Traders Pounce On 'Tiny Float' PlayOctober 13, 2025 | msn.comMannatech Extends Loan Repayment to March 2027September 12, 2025 | tipranks.comMannatech trading halted, volatility trading pauseAugust 14, 2025 | msn.comMannatech Reports Financial Results for Second Quarter 2025August 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, MIRA, GOSS, and GRCE Company DescriptionsGossamer Bio NASDAQ:GOSS$0.19 +0.02 (+12.53%) Closing price 04:00 PM EasternExtended Trading$0.19 0.00 (-0.97%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Grace Therapeutics NASDAQ:GRCE$2.53 +0.16 (+6.75%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.05 (-2.13%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.MIRA Pharmaceuticals NASDAQ:MIRA$0.95 +0.01 (+1.07%) Closing price 04:00 PM EasternExtended Trading$0.93 -0.02 (-2.29%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Mannatech NASDAQ:MTEX$5.04 -0.12 (-2.33%) As of 03:51 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
